NVAX · Novavax Inc

-

Please sign in to comment on NVAX

1 Comment

Admin

4 years, 11 months ago

Novavax, Inc is currently in a long term uptrend where the price is trading 32.1% above its 200 day moving average.

From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.5.

Novavax, Inc's total revenue rose by 3072.2% to $280M since the same quarter in the previous year.

Its net income has dropped by 457.9% to $-178M since the same quarter in the previous year.

Finally, its free cash flow fell by 612.0% to $-171M since the same quarter in the previous year.

Based on the above factors, Novavax, Inc gets an overall score of 3/5.

Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
ISIN	US6700024010

Target Price	13.7778
Beta	2.63
Market Cap	2B
PE Ratio	3.73
Dividend Yield	None

ABOUT

Novavax Inc

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NVAX · Novavax Inc

-

Novavax Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Novavax Inc using a moving average strategy